-

Bruker Announces Acquisition of Tornado Spectral Systems to Expand Its Biopharma Process Analytical Technology (PAT) Product Portfolio

MISSISSAUGA, Ontario--(BUSINESS WIRE)--Bruker (Nasdaq: BRKR) today announced the acquisition of Tornado Spectral Systems Inc., a Canadian company specializing in process Raman instruments, primarily used in pharma and biotech quality control applications. Tornado, with over a decade of experience in innovative and industry-proven Raman solutions, will enhance Bruker’s biopharma PAT portfolio with its well-established products. Financial details were not disclosed.

Tornado's patented High-Throughput Virtual Slit (HTVS™) technology measures highest-quality spectra even in difficult Raman analyses. Tornado’s portfolio of Raman analyzers includes the HyperFlux™ PRO Plus, Process Guardian™ and SuperFlux™, all with excellent performance compared to traditional process Raman spectrometers, for more accurate chemical identification and quantification in mixtures and at low concentrations. Tornado analyzers also allow faster measurements of dynamic reactions, and with low laser power they permit safe operation even in hazardous environments.

Tornado’s product line also includes rugged, high-performance Raman probes for immersion, flow cell, non-contact and large-spot measurements, each optimized for different process environments. Tornado analyzers can be multiplexed with a fiber-switch accessory, with one analyzer monitoring up to eight probes at eight different sampling points.

Dr. Andreas Kamlowski, President of Bruker Optics, stated: “The acquisition of Tornado process Raman technology and product is a great fit to expand our range of biopharma PAT analyzers. We warmly welcome the talented Tornado team with valuable applications expertise and years of experience.”

Mr. Ambrish Jaiswal, the CEO of Tornado Spectral Systems, commented: “The Tornado team is proud to join Bruker. We believe that Bruker provides the ideal environment for our ongoing advancements in PAT, and we look forward to further expanding and enhancing Bruker's spectroscopic process portfolio.”

About Tornado Spectral Systems
Founded in 2013, Tornado Spectral Systems designs, manufactures and sells chemical analysis systems based on Raman spectroscopy. Tornado’s non-destructive, real-time measurement solutions offer numerous benefits for established analytical practice and facilitate broader application of Raman methods for pharmaceutical, petrochemical, biotech, and other applications. Tornado’s headquarters is located in Mississauga, Canada, housing sales and marketing, engineering, technical support, and operations. For more information, please visit: https://tornado-spectral.com

About Bruker Corporation
Bruker is enabling scientists to make breakthrough discoveries and develop new applications that improve the quality of human life. Bruker’s high performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity and customer success in life science molecular and cell biology research, in applied and pharma applications, in microscopy and nanoanalysis, as well as in industrial applications. Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics. For more information, please visit: www.bruker.com.

Contacts

Investors:
Justin Ward
Sr. Director, Investor Relations & Corporate Development
Bruker Corporation
+1 (978) 313-5800
Investor.Relations@bruker.com

Media:
Michael Mueller
Marketing Manager
Bruker Optics GmbH & Co. KG
+49 7243 504 2652

Bruker Corporation

NASDAQ:BRKR

Release Versions
$Cashtags
Hashtags

Contacts

Investors:
Justin Ward
Sr. Director, Investor Relations & Corporate Development
Bruker Corporation
+1 (978) 313-5800
Investor.Relations@bruker.com

Media:
Michael Mueller
Marketing Manager
Bruker Optics GmbH & Co. KG
+49 7243 504 2652

Social Media Profiles
More News From Bruker Corporation

Chemspeed and SciY Announce Self‑Driving Laboratory Platform Integrating Automation, Analytics and AI Orchestration

BOSTON--(BUSINESS WIRE)--At SLAS2026, Chemspeed Technologies, a leader in the automation and digitalization of R&D and QC laboratories, and SciY, a leader in scientific and laboratory management software focused on lab standardization and AI-readiness, today introduce their open Self‑Driving Lab (SDL) platform. Their Self-Driving Lab platform is designed to accelerate research and development (R&D), quality control (QC) and chemical and biomolecular manufacturing workflows. The SDL enab...

Bruker Introduces iNTApharma™, a Label‑Free Platform for Nanoparticle Characterization in mRNA Drug and Gene Therapy Development and QC

BILLERICA, Mass.--(BUSINESS WIRE)--Bruker Corporation today announced the launch of iNTApharma, a label‑free characterization platform that provides single‑particle sensitivity for the quantitative analysis of nanoscale bioparticles in native aqueous media. Introduced at SLAS 2026 in Boston, iNTApharma delivers size and concentration measurements within minutes, supporting research, therapy development and quality control workflows that require direct, native‑state assessment of bio-nanoparticl...

Bruker Announces Quarterly Preferred Stock Dividend

BILLERICA, Mass.--(BUSINESS WIRE)--Bruker Corporation (Nasdaq: BRKR, BRKRP) today announced that its Board of Directors (“Board”) has approved payment of a quarterly cash dividend in the amount of $3.9844 per share on the Company’s 6.375% Mandatory Convertible Preferred Stock, Series A, par value $0.01 per share (the “Mandatory Convertible Preferred Stock Dividend”). The Mandatory Convertible Preferred Stock Dividend will be paid on March 2, 2026 to stockholders of record as of February 15, 202...
Back to Newsroom